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developed to streamline patient screening, study enrollment and ensure patient follow up.
Patient care protocols and specific study instructions were developed and distributed to all
healthcare providers. The TAVR research model proved to be a excellent platform for
management of a complex clinical trial and was used as a template for the transition to a
commercial TAVR program.
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Hypoxia Reoxygenation-induced Myocardial Cell Apoptosis Can Be Rescued By
Frizzled-2 Suppression
Zhou Shanshan, Chen Yundai
The PLA General Hospital, Beijing, China
Background: This study is aiming to find the signal transduction underlying calcium
overloading caused cell apoptosis phenomenon post myocardial treatments.
Methods: For the information of Wnt5a/frizzled-2 signal pathway in mammalian
cardiac cells were hardly seen before, first we needed to confirm the gene and protein
expression of the effectors (wnt5a;frizzle-2;p-camkii, the marker presents the activation of
this signal) which consisting this signal within myocardial cells, through q-rtpcr, western
blot and some specific methods in detail.
Second, we transfected the cells with frizzled-2 gene in order to activate this pathway,
and recorded the intracellular and cellular effects like cell apoptosis. Third, we used Stealth
RNAi to conduct frizzled-2 gene suppression, then observed the following effects. Results
indicated the role of Wnt5a/Frizzled-2 pathway played in calcium overloading process
and cell apoptosis. Next, we analyzed the expression of the effectors of this pathway after
the cells were conducted through hypoxia/reoxygenation treatment. In this part, the same
testing objects and methods were used to consistent with different treatment groups.
Results: First, results from simple cell interference test showed that wnta5a, frizzled-2
and p-camkii is stable expressing in cardiac cells.
Second, High expression of p-CamkII followed by intracellular accumulation of
calcium post frizzled-2 transfection indicates the activation of wnt5a/Frizzled-2 pathway.
This was proved by gene suppression of frizzled-2 on the membrane: down regulation of
frizzled-2 gene caused down expression of Frizzled-2 protein and p-CamkII marker, also
the calcium accumulation and apoptosis.
Third, data from hypoxia/reoxygenation treatment group is found have the same trend
echoes to part 1. Whatever in hypoxia group or in reoxygenation group, expression of
Frizzled-2 on the cell membrane determines the character of wnt5a and downstream
effectors, and eventually affects the intracellular calcium accumulation and apoptosis.
Conclusion: We hypothesis that activation of wnt5a/Frizzled-2 pathway post myocar-
dial treatments could be a main reason causing calcium overloading and cell apoptosis.
Results have proved our hypothesis, and this is the first paper in this area in evaluating this
signal pathway within mammalian cardiac cells and raising a possible concept that
activation of this signal pathway might be one of the mechanisms underlying cell apoptosis
post myocardial treatments.
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Exendin-4 Improves the Survival and Therapeutic Efficacy of Implanted Stem Cells
Following Myocardial Infarction
Liu Jianfeng, Sr., Chen Yundai, Wang Haibin, Liu Zhiqiang, Yang Junjie, Tian Feng,
Wang Changyong
Chinese PLA General Hospital, Beijing, China
Background: The poor survival rate of stem cell transplantation in ischemic myocardial
microenvironment is a major obstacle for stem cell therapy. Exendin-4 holds the potential
of cardioprotective effect based on their pleiotropic activity. This study was designed to
investigate whether the combination of Exendin-4 and adipose derived stem cells
(ADSCs) could significantly improve the stem cells survival, engraftment and contribute
to myocardial repair after myocardial infarction.
Material and Methods: The oxidative stress of cultured ADSCs was induced by H2O2
administration in vitro. The protective effect of Exendin-4 was investigated by dihydro-
ethidium (DHE) staining and Live/Dead assay. For in vivo studies, MI was induced by
the left anterior descending artery ligation in adult male Sprague-Dawley rats. ADSCs
carrying dual-fusion (TF) reporter gene (fluc-mrfp) were quickly injected into border zone
of myocardial infarction in rats treated with or without Exendin-4. PBS alone was injected
as control. Multi-techniques were used to assess the beneficial effects after transplantation.
Results: The results showed that exendin-4 decreased ros level and reduced the necrosis
of adscs suffered from oxidative stress significantly in vitro. one week after transplantation,
inflammatory cells and oxidative stress of heart in exendin-4 group were decreased
markedly than that in control group. four weeks after transplantation, the cardiac function
evaluated by echocardiogram and MicroPET/ct improved significantly, while the infarct
size and fibrotic area decreased significantly in Exendin-4adscs group compared with
that of other groups. both exendin-4 group and adscs group also improved myocardial
performance. bioluminescence imaging showed exendin-4 promoted adscs survival sig-
nificantly in vivo. histology examination showed that the combination of exendin-4 and
adscs could reduce myocardial fibrosis, decrease myocardial apoptosis, increase vessel
density, and enhance cardiogenic differentiation of adscs. western blotting demonstrated
that oxidative stress and inflammation were significantly inhibited in the border area of
infarction in Exendin-4adscs group.
Conclusion: Through regulating the post-infarct microenvironment, exendin-4 com-
bined with adscs can improve the survival and therapeutic efficacy of implanted stem cells.
this study suggests the potential of exendin-4 for stem cell based heart regeneration.
Atherosclerosis
CRT-113
A Reproducible Animal Model of Calcified Atherosclerotic Plaque from a
Cylindrical Bone Marrow Allograft Implanted in the Porcine Coronary and
Peripheral Vasculature
Michael Frie, Mark Smith
American Preclinical Services, Coon Rapids, MN
A reproducible animal model of calcified atherosclerotic plaque exhibiting properties
similar to those observed in the human population has proven difficult to develop. We
therefore investigated the use of a bone marrow plug, placed interventionally in the
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coronary and peripheral arteries, to simulate the properties of a calcific chronic partial
occlusion (CPO) lesion for the evaluation of catheter based technologies.
Forty-one pigs were prepped sterilely for creation of the CPO. An introducer sheath
was placed in the carotid artery for vascular access. Angiograms of the left anterior
descending (LAD) coronary artery and the iliac tree were obtained. A section of artery
measuring 2.8 - 3.0mm in diameter was identified and targeted for implantation with the
plug. A cylinder of bone marrow measuring 3mm in outer diameter by 10mm in length
was obtained from the rib of a donor animal and a lumen measuring approximately
1.6mm in diameter was created. The bone plug was loaded into a 9Fr guide catheter,
tracked to the targeted location within the artery and deployed. Angiography immediately
post deployment demonstrated an average lesion lumen diameter of 1.32mm (1.08 -
2.35mm).
Twenty-nine of forty-one pigs (implanted with a total of thirty-five bone plugs)
survived to the scheduled follow-up procedure (between 4 and 14 days). Thirty of the
thirty-five surviving implanted bone plugs were patent, with follow-up angiography
demonstrating reduced blood flow through the lesion, with an average lesion lumen
diameter of 1.20mm (0 - 2.59mm).
We can reliably create a porcine coronary model simulating a calcific partial occlusion,
which can be used for the evaluation of interventional technologies and platforms used to
treat coronary and peripheral artery disease. The results of previous studies have
demonstrated successful deployment of a chronic total occlusion (CTO) version of the
bone plug in the coronary and peripheral vasculature. Additionally, we have successfully
implanted larger bone marrow plugs (measuring 3.0 - 5.5mm in outer diameter) and
demonstrated the ability to reduce the calcium content of the bone marrow plug prior to
deployment, thereby decreasing the hardness of the lesion.
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Correlation Between Carotid Ultrasonographic Parameters And Syntax Score
According To The Extent Of Coronary Artery Disease
Seung-Hwan Lee, Jun-Won Lee, Young-Jin Youn, Sung Gyun Ahn, Min-Soo Ahn,
Jang-Young Kim, Byung-Su Yoo, Junghan Yoon, Kyung-Hoon Choe
Yonsei University Wonju Christian Hospital, Wonju, Korea, Republic of
Background: Carotid ultrasonography is a good non-invasive modality to evaluate
atherosclerotic changes. Intima-media thickness (IMT) is a well-established surrogate
marker of coronary atherosclerosis. But, the role of other carotid parameters for predicting
coronary artery disease (CAD) is still lack of evidence. Therefore, we evaluated the
correlation between carotid parameters and SYNTAX score (SS) representing the severity
and extent of CAD. We also investigated whether carotid parameters predict the presence
of CAD or not.
Methods: Total 663 of 1698 patients (408 men, mean age: 64.1  11.9 years) who
performed both carotid ultrasonography and coronary angiography during admission from
Sep 2011 to Aug 2012 were studied. The patients were divided into three groups: normal
or minimal CAD, 1 vessel disease (VD) and 2VD. Plaque score (PS) was defined as a
numerical summation of the presence of plaque in 4 different locations of both carotid
arteries. Maximum % diameter stenosis (DS) and area stenosis (AS) were measured at the
narrowest portion in longitudinal and short axis view.
Results: The old age, male gender, diabetes mellitus and smoking were significantly
related to the extent of CAD. All carotid parameters showed significant relationship with
the extent of CAD. Mean carotid IMT, maximum carotid IMT, PS, %AS and %DS
were weakly but significantly correlated with SS (r0.226, 0.162, 0.336, 0.361, 0.318,
respectively, all p value  0.001). After adjusted for classic risk factors, PS was the best
predictor for CAD (Odds ratio 1.576, 95% confidence interval 1.365-1.820, p0.001).
The diagnostic accuracy of PS for the detection of CAD by the area under the receiver
operating characteristics curve was 0.702 (95% confidence interval 0.661-0.743,
p0.001).
Conclusion: All carotid parameters were weakly but significantly correlated with
SYNTAX score. PS was a good predictor for coronary artery disease. Long-term
follow-up is warranted to discriminate clinical outcomes using carotid ultrasonographic
parameters.
Other
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Demographics Of Study Participants In Clinical Trials For Cardiovascular Drugs
Approved By FDA From 2010 To 2011
Noha Eshera, Amber Marsh, Leslie Chinn, Lei Zhang, Emmanuel O Fadiran
Food and Drug Administration, Silver Spring, MD
Objectives: Historically, women and minorities have been underrepresented in clinical
trials of drugs to treat cardiovascular disease (CVD). To accurately assess the safety and
efficacy of CVD drugs, the U.S. Food and Drug Administration (FDA) has made a
conscious effort to ensure adequate representation of women and minorities in clinical
drug trials through guidance documents and regulations. The purpose of this study is to
assess the participation of women and racial/ethnic minorities in FDA-reviewed CVD
drug trials that were included in New Drug Applications (NDAs) approved between 2010
and 2011.
Methods: The sex and race/ethnicity of subjects in all CVD drug clinical trials submitted
to FDA in support of NDAs approved between January 2010 and December 2011 were
assessed from final clinical study reports. The reports were accessed via internal FDA
databases.
Results: Four drugs (1 per NDA) indicated for hypertension (HTN), acute coronary
syndrome (ACS), non-valvular atrial fibrillation (NAF) and deep vein thrombosis/
pulmonary embolism (DVT/PE) after joint replacement surgery were approved during
the period studied. A total of 231 clinical trials classified as phase 1, 2, or 3 studies were
submitted to the NDAs. There were 107,156 subjects included in these studies.
Demographic analysis (shown in Table 1) indicated that the mean participation of women
in these trials was 41% and the majority of the trial subjects were Caucasians (79%). When
analyzed by the phase of the trials, mean female participation was 21%, 43% and 42% for
Phase 1, 2 and 3 respectively.
Table 1. Subject Demographics in CVD drug trials of NDAs approved by
FDA from 2010 to 2011.
Overall
N107156
HTN
N10558
ACS
N21127
NAF
N33662
DVT/PE
N41809
Sex
Females N (%) 44169 (41) 4643 (44) 5960 (28) 13960 (41) 19606 (47)
Males N (%) 62987 (59) 5915 (56) 15167 (72) 19702 (59) 22203 (53)
Race
Caucasian N (%) 84587 (79) 7201 (68) 18942 (90) 26291 (78) 32153 (77)
Black N (%) 2571 (2.4) 1254 (12) 462 (2.0) 228 (6.8) 627 (1.5)
Asian N (%) 9077 (8.5) 1058 (10) 1321 (6.3) 1085 (3.2) 5613 (13)
Hispanic* N (%) 1969 (1.8) 1119 (11) 66 (3.1) 0 784 (1.9)
Other** N (%) 2242 (2.1) 1027 (9.7) 343 (1.6) 159 (0.5) 713 (1.7)
Unknown^ N (%) 2111 (2.0) 0 0 466 (1.4) 1645 (3.9)
*Depending on the study, Hispanic subjects were counted either as Caucasian or a separate race/
ethnicity category. **Includes those classified as American Indian/Alaska Native, Hawaiian/Pacific
Islander, Multiracial or Other. ^Any participants whose race is listed as missing or who participated in
studieswhere therewere legal concernsaboutcollecting racedata (applied in someEuropean trials).
Conclusions: The overall inclusion of women in these CVD drug trials is comparable to
the overall female CVD population (51%) in the US. However, women are largely
underrepresented in the Phase 1 trials, during which much of the pharmacokinetics and
pharmacodynamics of new drugs are evaluated.
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